Web4 jun. 2024 · The VISION trial looked at a new type of cancer treatment, called 177Lu-PSMA-617 (also known as Lutetium-177 or lutetium therapy). What’s exciting about lutetium therapy is that it’s delivered straight to cancer cells through an innovative mechanism that reduces side-effects and can help extend the life of men with advanced … Web17 jun. 2024 · Lutetium-177-PSMA-617 Radioligand Therapy in Oligo-metastatic Hormone Sensitive Prostate Cancer. Radioligand therapy (RLT) using Lutetium-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer. This tumor-specific treatment is directed against prostate-specific membrane antigen (PSMA), …
Behind the headlines lutetium therapy Prostate Cancer UK
WebPCRI's CEO, Alex Scholz, asks medical oncologist, Mark Scholz, MD, about lutetium-177, an injectable targeted radiotherapy that works with the new PSMA/PET s... Web26 apr. 2024 · Lutetium Lu 177 vipivotide tetraxetan is used to treat prostate-specific membrane antigen (PSMA)-positive, metastatic castration-resistant prostate cancer (mCRPC). These advanced metastatic prostate cancers do not respond to chemotherapy or treatments that lower testosterone. sight word fly swatter game
PSMA-Therapie Universitätsklinikum Tübingen - uni-tuebingen.de
Web13 apr. 2024 · This first-in-patient study showed that OTL78 was well tolerated and had the potential to improve prostate cancer detection. Optimal dosing was 0·03 mg/kg, 24 h … Web23 mrt. 2024 · The Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, formerly referred to as 177Lu-PSMA-617) to treat adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer. WebZang S, Shao G, Cui C, Li TN, Huang Y, Yao X, et al. 68Ga-PSMA-11 PET/CT for Prostate Cancer Staging and Risk Stratification in Chinese Patients. Oncotarget (2024) 8:12247–58. doi: 10.18632/oncotarget.14691. ... 177 Lu, prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), prostate-specific membrane antigen (PSMA), ... the prime source